secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREVENA INC (—)
CIK:        0001429560
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001104659-24-041321
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevena Q4 net loss $16.5M; reduces OLINVYK support, reviews alternatives
-------------------------------------------------------------------------

- Net loss $16.5M ($1.06/share) vs $7.0M ($0.73/share) in Q4 2022.
- FY2023 net loss $40.3M ($3.16/share); cash $33.0M as of Dec 31, 2023.
- Reducing OLINVYK commercial support; reviewing strategic alternatives including sale or license.
- TRV045 advances toward Phase 2 readiness with positive PoC data in neuropathic pain and epilepsy.
- TRV045 showed no lymphopenia, bradycardia, or BP changes vs other S1P modulators.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429560/000110465924041321/0001104659-24-041321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429560/000110465924041321/tm2410264d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-041321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer